HER2+ (Positive) Breast Cancer
Archives for December 2018
Discussion List
-
Kadcyla Better Than Herceptin for Early-Stage, HER2+ Residual BC
Kadcyla Seems Better Than Herceptin for Early-Stage, HER2-Positive Residual Breast Cancer December 13, 2018 The KATHERINE trial suggests that Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) improves disease-free survival compared to Herceptin (chemical name: trastuzumab) in people diagnosed with early-stage,…
Join Us on Zoom: Upcoming virtual meetups. Read more...